Fragki Styliani, Hoogenveen Rudolf, van Oostrom Conny, Schwillens Paul, Piersma Aldert H, Zeilmaker Marco J
Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Centre for Statistics, Informatics and Modelling, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Toxicology. 2022 Jan 15;465:153060. doi: 10.1016/j.tox.2021.153060. Epub 2021 Dec 4.
With the increasing application of cell culture models as primary tools for predicting chemical safety, the quantitative extrapolation of the effective dose from in vitro to in vivo (QIVIVE) is of increasing importance. For developmental toxicity this requires scaling the in vitro observed dose-response characteristics to in vivo fetal exposure, while integrating maternal in vivo kinetics during pregnancy, in particular transplacental transfer. Here the transfer of substances across the placental barrier, has been studied using the in vitro BeWo cell assay and six embryotoxic compounds of different kinetic complexity. The BeWo assay results were incorporated in an existing generic Physiologically Based Kinetic (PBK) model which for this purpose was extended with rat pregnancy. Finally, as a "proof of principle", the BeWo PBK model was used to perform a QIVIVE based on developmental toxicity as observed in various different in vitro toxicity assays. The BeWo results illustrated different transport profiles of the chemicals across the BeWo monolayer, allocating the substances into two distinct groups: the 'quickly-transported' and the 'slowly-transported'. BeWo PBK exposure simulations during gestation were compared to experimentally measured maternal blood and fetal concentrations and a reverse dosimetry approach was applied to translate in vitro observed embryotoxicity into equivalent in vivo dose-response curves. This approach allowed for a direct comparison of the in vitro dose-response characteristics as observed in the Whole Embryo Culture (WEC), and the Embryonic Stem Cell test (cardiac:ESTc and neural:ESTn) with in vivo rat developmental toxicity data. Overall, the in vitro to in vivo comparisons suggest a promising future for the application of such QIVIVE methodologies for screening and prioritization purposes of developmental toxicants. Nevertheless, the clear need for further improvements is acknowledged for a wider application of the approach in chemical safety assessment.
随着细胞培养模型作为预测化学物质安全性的主要工具的应用日益增加,从体外到体内有效剂量的定量外推(QIVIVE)变得越来越重要。对于发育毒性而言,这需要将体外观察到的剂量反应特征按比例换算为体内胎儿暴露量,同时整合孕期母体的体内动力学,尤其是胎盘转运。在此,使用体外BeWo细胞试验和六种动力学复杂性不同的胚胎毒性化合物研究了物质跨胎盘屏障的转运。将BeWo试验结果纳入现有的通用生理药代动力学(PBK)模型,为此该模型扩展了大鼠孕期的情况。最后,作为“原理验证”,使用BeWo PBK模型基于在各种不同体外毒性试验中观察到的发育毒性进行QIVIVE。BeWo试验结果说明了化学物质在BeWo单层细胞上的不同转运情况,将这些物质分为两个不同的组:“快速转运”组和“缓慢转运”组。将孕期BeWo PBK暴露模拟结果与实验测量的母体血液和胎儿浓度进行比较,并应用反向剂量测定法将体外观察到的胚胎毒性转化为等效的体内剂量反应曲线。这种方法可以直接比较全胚胎培养(WEC)和胚胎干细胞试验(心脏:ESTc和神经:ESTn)中观察到的体外剂量反应特征与体内大鼠发育毒性数据。总体而言,体外到体内的比较表明,此类QIVIVE方法在发育毒物的筛选和优先级排序方面具有广阔的应用前景。然而,也认识到为了该方法在化学安全性评估中的更广泛应用,显然需要进一步改进。